Healthcare / Medical DevicesKOSDAQ
$3740.00
+240.00 (+6.86%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-6.7B · quality 74.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
34/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$56.5B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-13.8%
↓Gross Margin
28.1%
↓Debt/Equity
0.06
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+48.4%
FCF CAGR
—
FCF margin
-153.7%
FCF / Net income
1.77x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $4.38B · net income $-3.80B · FCF $-6.73B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $4.38B | $4.38B | $3.56B | $4.50B | $1.34B |
| Net Income | $-3.80B | $-3.80B | $-4.00B | $-5.04B | $-9.74B |
| EBITDA | $-1.79B | $-1.79B | $-2.44B | $-2.33B | $-6.78B |
| EPS | -252.00 | -252.00 | -293.00 | -660.00 | -1947.00 |
| Gross Margin | 28.1% | 28.1% | 37.8% | 31.7% | 11.9% |
| Operating Margin | -94.9% | -94.9% | -120.9% | -64.6% | -248.9% |
| Net Margin | -86.9% | -86.9% | -112.3% | -112.2% | -727.7% |
| Balance Sheet | |||||
| Debt/Equity | 0.06 | 0.06 | 0.07 | 0.19 | -0.12 |
| Current Ratio | 15.74 | 15.74 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-6.73B | $-6.73B | $-7.59B | $-3.94B | $-4.50B |
| Returns | |||||
| ROE | -13.8% | -13.8% | -12.8% | -39.3% | 48.6% |
| Valuation | |||||
| P/B | 2.04 | 2.04 | 2.09 | — | — |
| Growth & Yield | |||||
| Revenue Growth | 22.8% | 22.8% | -20.7% | 236.0% | — |
| EPS Growth | 14.0% | 14.0% | 55.6% | 66.1% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+0.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-293.00 → -252.00
Residual
+0.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.